Page 206 - Read Online

Page 16 of 18 Borniger. J Cancer Metastasis Treat 2019;5:23 I http://dx.doi.org/10.20517/2394-4722.2018.107

49. McAlpine CS, Kiss MG, Rattik S, He S, Vassalli A, et al. Sleep modulates haematopoiesis and protects against atherosclerosis. Nature
2019;566:383-7.
50. Akhtar RA, Reddy AB, Maywood ES, Clayton JD, King VM, et al. Circadian cycling of the mouse liver transcriptome, as revealed by
cDNA microarray, is driven by the suprachiasmatic nucleus. Curr Biol 2002;12:540-50.
51. O’Neill JS, Maywood ES, Chesham JE, Takahashi JS, Hastings MH. cAMP-dependent signaling as a core component of the mammalian
circadian pacemaker. Science 2008;320:949-53.
52. Partch CL, Green CB, Takahashi JS. Molecular architecture of the mammalian circadian clock. Trends Cell Biol 2014;24:90-9.
53. Stephan FK, Zucker I. Circadian rhythms in drinking behavior and locomotor activity of rats are eliminated by hypothalamic lesions. Proc
Natl Acad Sci U S A 1972;69:1583-6.
54. Baver SB, Pickard GE, Sollars PJ, Pickard GE. Two types of melanopsin retinal ganglion cell differentially innervate the hypothalamic
suprachiasmatic nucleus and the olivary pretectal nucleus. Eur J Neurosci 2008;27:1763-70.
55. Hattar S, Liao HW, Takao M, Berson DM, Yau KW. Melanopsin-containing retinal ganglion cells: architecture, projections, and intrinsic
photosensitivity. Science 2002;295:1065-70.
56. Borniger JC, Cisse YM, Surbhi, Nelson RJ. Reciprocal regulation of circadian rhythms and immune function. Curr Sleep Med Rep
2017;3:93-103.
57. Scheiermann C, Kunisaki Y, Frenette PS. Circadian control of the immune system. Nat Rev Immunol 2013;13:190-8.
58. Cadenas C, van de Sandt L, Edlund K, Lohr M, Hellwig B, et al. Loss of circadian clock gene expression is associated with tumor
progression in breast cancer. Cell Cycle Georget Tex 2014;13:3282-91.
59. Stevens RG. Circadian disruption and breast cancer: from melatonin to clock genes. Epidemiol Camb Mass 2005;16:254-8.
60. Van Dycke KCG, Rodenburg W, van Oostrom CTM, van Kerkhof LWM, Pennings JLA, et al. Chronically alternating light cycles increase
breast cancer risk in mice. Curr Biol 2015;25:1932-7.
61. Papagiannakopoulos T, Bauer MR, Davidson SM, Heimann M, Subbaraj L, et al. Circadian rhythm disruption promotes lung tumorigenesis.
Cell Metab 2016;24:324-31.
62. Davidson SM, Papagiannakopoulos T, Olenchock BA, Heyman JE, Keibler MA, et al. Environment impacts the metabolic dependencies of
ras-driven non-small cell lung cancer. Cell Metab 2016;23:517-28.
63. He B, Nohara K, Park N, Park YS, Guillory B, et al. The small molecule nobiletin targets the molecular oscillator to enhance circadian
rhythms and protect against metabolic syndrome. Cell Metab 2016;23:610-21.
64. Chen J, Chen AY, Huang H, Ye X, Rollyson WD, et al. The flavonoid nobiletin inhibits tumor growth and angiogenesis of ovarian cancers
via the Akt pathway. Int J Oncol 2015;46:2629-38.
65. Li N, Zhang Z, Jiang G, Sun H, Yu D. Nobiletin sensitizes colorectal cancer cells to oxaliplatin by PI3K/Akt/MTOR pathway. Front Biosci
Landmark Ed 2019;24:303-12.
66. Sp N, Kang DY, Joung YH, Park JH, Kim WS, et al. Nobiletin inhibits angiogenesis by regulating Src/FAK/STAT3-mediated signaling
through PXN in ER+ breast cancer cells. Int J Mol Sci 2017;18:E935.
67. Bedrosian TA, Herring KL, Walton JC, Fonken LK, Weil ZM, et al. Evidence for feedback control of pineal melatonin secretion. Neurosci
Lett 2013;542:123-5.
68. Borniger JC, Nelson RJ. Photoperiodic regulation of behavior: peromyscus as a model system. Semin Cell Dev Biol 2017;61:82-91.
69. Hardeland R, Poeggeler B. Non-vertebrate melatonin. J Pineal Res 2003;34:233-41.
70. Tan DX, Hardeland R, Manchester LC, Paredes SD, Korkmaz A, et al. The changing biological roles of melatonin during evolution: from an
antioxidant to signals of darkness, sexual selection and fitness. Biol Rev 2010;85:607-23.
71. Teclemariam-Mesbah R, Ter Horst GJ, Postema F, Wortel J, Buijs RM. Anatomical demonstration of the suprachiasmatic nucleus-pineal
pathway. J Comp Neurol 1999;406:171-82.
72. Carrillo-Vico A, Calvo JR, Abreu P, Lardone PJ, García-Mauriño S, et al. Evidence of melatonin synthesis by human lymphocytes and its
physiological significance: possible role as intracrine, autocrine, and/or paracrine substance. FASEB J 2004;18:537-9.
73. Carrillo-Vico A, Lardone PJ, Álvarez-Sánchez N, Rodríguez-Rodríguez A, Guerrero JM. Melatonin: buffering the immune system. Int J
Mol Sci 2013;14:8638-83.
74. Hardeland R, Cardinali DP, Srinivasan V, Spence DW, Brown GM, et al. Melatonin--a pleiotropic, orchestrating regulator molecule. Prog
Neurobiol 2011;93:350-84.
75. Erren TC, Falaturi P, Morfeld P, Knauth P, Reiter RJ, et al. Shift work and cancer. Dtsch Ärztebl Int 2010;107:657-62.
76. Davis S, Mirick DK, Stevens RG. Night shift work, light at night, and risk of breast cancer. J Natl Cancer Inst 2001;93:1557-62.
77. James P, Bertrand KA, Hart JE, Schernhammer ES, Tamimi RM, et al. Outdoor light at night and breast cancer incidence in the Nurses’
Health Study II. Environ Health Perspect 2017;125:087010.
78. Johns LE, Jones ME, Schoemaker MJ, McFadden E, Ashworth A, et al. Domestic light at night and breast cancer risk: a prospective analysis
of 105 000 UK women in the generations study. Br J Cancer 2018;118:600-6.
79. Blask DE, Brainard GC, Dauchy RT, Hanifin JP, Davidson LK, et al. Melatonin-depleted blood from premenopausal women exposed to
light at night stimulates growth of human breast cancer xenografts in nude rats. Cancer Res 2005;65:11174-84.
80. Hill SM, Belancio VP, Dauchy RT, Xiang S, Brimer S, et al. Melatonin: an inhibitor of breast cancer. Endocr Relat Cancer 2015;22:R183-
204.
81. Mao L, Dauchy RT, Blask DE, Dauchy EM, Slakey LM, et al. Melatonin suppression of aerobic glycolysis (Warburg effect), survival
signalling and metastasis in human leiomyosarcoma. J Pineal Res 2016;60:167-77.
82. Reiter RJ, Rosales-Corral SA, Tan DX, Acuna-Castroviejo D, Qin L, et al. Melatonin, a full service anti-cancer agent: inhibition of
initiation, progression and metastasis. Int J Mol Sci 2017;18:E843
83. Xiang S, Dauchy RT, Hauch A, Mao L, Yuan L, et al. Doxorubicin resistance in breast cancer is driven by light at night induced disruption
of the circadian melatonin signal. J Pineal Res 2015;59:60-9.